Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLOB in tibial fracture at risk of delayed union or non-union
2018-001054-96Phase 2Completed
- Sponsor
- BioSenic
- Start
- Jan 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in tibia fracture, delayed bone healing and fracture nonunion comparing ALLOB with Placebo (2 arms). Primary endpoint: Radiological success at Week 12. Started Jan 2020; status: completed.
02
Drugs
allogeneic osteoblastic cells
03
Conditions
tibia fracturedelayed bone healingfracture nonunion
Beyond the preview
Go deeper on 2018-001054-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001054-96.